Guangxi Chunzhengtang Pharmaceutical Co., Ltd.

Main purpose: To investigate the in vivo course of melogabalin after a single oral administration of melogabalin besylate tablets (test preparation, specification: 5 mg) produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd. and owned by Jiuhua Huayuan Pharmaceutical (Guilin) Co., Ltd. and melogabalin besylate tablets (reference preparation, T-LIGE®, specification: 5 mg) produced by Daiichi Sankyo Co., Ltd. in healthy subjects on an empty stomach, estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in the fasting state, and provide a basis for the production registration application of the test preparation.

Main purpose: With healthy subjects as the test subjects, a randomized, open, two-period, two-sequence, double-crossover design was used to investigate the in vivo time course of trazodone after a single oral administration of trazodone hydrochloride sustained-release tablets (test preparation, specification: 150 mg) produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd. (held by Jiuhua Huayuan Pharmaceutical (Guilin) Co., Ltd.) and trazodone hydrochloride sustained-release tablets (reference preparation, trade name: Trittico®\Trittico®, specification: 150 mg) produced by Az.Chim.Riun.Angelini Francesco Acraf S.P.A. on fasting and after meals, estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in fasting and after meals, and provide a basis for the production registration application of the test preparation. Secondary purpose: To evaluate the safety of the test preparation and reference preparation (trade name: Trittico®\Trittico®) of trazodone hydrochloride sustained-release tablets in healthy subjects.

Upadacitinib sustained-release tablets (specification: 15 mg) produced by Jiuhua Huayuan Pharmaceutical (Guilin) Co., Ltd. were used as the test preparation, and upadacitinib sustained-release tablets (Rinvoq®/Rinvoq®, specification: 15 mg) produced by ABBVIE DEUTSCHLAND GMBH & CO. KG were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent; at the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.